Physician profile
Dee A Roach
NPI 1275542854
$823.79
in general payments reported to CMS, 2019-2025
16 companies · $36.86 in 2025
The $36.86 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166 · 2020: $211 · 2021: $153 · 2022: $110 · 2023: $119 · 2024: $27.82 · 2025: $36.86.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $183.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $210.53 | 2019-2025 | Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $153.54 | 2019-2021 | |
| Lilly USA, LLC | $110.14 | 2021-2024 | Trulicity, Mounjaro |
| Abbvie INC. | $50.03 | 2021-2025 | |
| Amgen INC. | $44.98 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $44.27 | 2022-2023 | |
| Eisai INC. | $40.07 | 2020 | |
| Sunovion Pharmaceuticals INC. | $38.04 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $25.79 | 2019-2020 | |
| Allergan, INC. | $21.65 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.98 | 2021 | |
| Smith+Nephew, INC. | $16.55 | 2023 | Grafix Pl, Stravix |
| E.R. Squibb & Sons, L.L.C. | $13.39 | 2022 | |
| Pfizer INC. | $13.23 | 2023 | |
| Tersera Therapeutics LLC | $11.64 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $10.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dee Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.